

On the horizon: Immunotherapy strategies for relapsed/refractory high-risk neuroblastoma

Faculty

Susan Cohn, MD, University of Chicago, Chicago, IL, USA

Daniel Morgenstern, MB BChir, PhD, The Hospital for Sick Children and the University of Toronto
Toronto, ON, Canada

Jaume Mora, MD, PhD, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu
Barcelona, Spain

Release date: January 15, 2021

Expiration date: January 15, 2022

Estimated time to completion: 1.5 hour

Available CME Credits:

- Physician continuing medical education (AMA) – up to 1.5 contact hours
- Continuing nursing education (ANCC) – up to 1.5 contact hours

Activity description

This webcast, On the horizon: Immunotherapy strategies for relapsed/refractory high-risk neuroblastoma, was originally presented as a live virtual, CME-certified 90-minute satellite symposium at the SIOP 2020 Virtual Congress.

Target audience

This activity is intended for/has been designed to meet the educational needs of oncologists, surgeons, radiologists, nurses, pharmacists, physician assistants, and other healthcare professionals involved in the management and treatment of patients with high-risk neuroblastoma.

Learning objectives

After completing this activity, the participant should be better able to:

- Recognize the unmet needs in patients with relapsed/refractory high-risk neuroblastoma
- Describe the rationale and role of immunotherapy for the treatment of high-risk neuroblastoma in the relapsed/refractory setting
- Evaluate the efficacy and safety profiles of anti-GD2-based immunotherapies
- Discuss the integration of current and emerging immunotherapies into conventional multimodality treatment and importance of a multidisciplinary approach to care

Joint accreditation statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Physician continuing medical education

The Postgraduate Institute for Medicine designates this enduring virtual activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing nursing education

The maximum number of hours awarded for this continuing nursing education activity is 1.5 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for advance practice registered nurses.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Method of participation and request for credit

There are no fees for participating in, and receiving CME credit for, this activity.

In order to claim credit, participants must complete the following procedures during the period January 15, 2021, through January 15, 2022.

1. Read the educational objectives, accreditation information, and faculty disclosures
2. View the webcast
3. Take the post-activity test and complete the evaluation
4. Download the certificate of CME credit

Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

| Faculty | Relationship identified with: |
|-----------------------------------|--|
| Susan Cohn, MD | Ownership interest (less than 5%) in AbbVie, Amgen, Eli Lilly and Company, Gilead, Novo Nordisk, Pfizer, Sanofi. |
| Daniel Morgenstern, MB BChir, PhD | Consulting fees from BMS, Boehringer Ingelheim, EUSA Pharma, Roche. |
| Jaume Mora, MD, PhD | Consulting fees from Y-mAbs Therapeutics, Inc. |

Planners and managers

The PIM planners and managers have nothing to disclose. The Ology planners and managers have nothing to disclose.

Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.



Financial support

This activity is supported by an independent educational grant from Y-mAbs Therapeutics, Inc.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

info@ologyeducation.org, www.ologyeducation.org

inquiries@pimed.com, www.pimed.com

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Media

Internet